FA
FUSN

Forefront Analytics’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Forefront Analytics’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,715
Closed -$161K – 70
2023
Q4 		$161K Sell
16,715
-16,970
-50% -$82.5K 0.08% 56
2023
Q3 		$87.6K Buy
33,685
+13,610
+68% +$43.6K 0.05% 55
2023
Q2 		$93.8K Buy
+20,075
New +$86.8K 0.05% 58

Other funds holding FUSN

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Forefront Analytics's FUSN Position: Q1 2024 in Review

Forefront Analytics sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2024, closing a stake of 16,715 shares — an estimated $161K sold.

Forefront Analytics first reported a position in FUSN in Q2 2023 and held it in 3 quarters. The position peaked at $161K in Q4 2023. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

  • Forefront Analytics reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2024 after selling out during the quarter.
  • Forefront Analytics sold 16,715 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2024, an estimated $161K.
  • Forefront Analytics first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2023 and held it in 3 quarters.
  • Forefront Analytics's Fusion Pharmaceuticals Inc. Common Shares position peaked at $161K in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2024.

Based on Forefront Analytics's 13F filing for Q1 2024, filed 15 May 2024.